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Abstract
Background: The pathophysiological basis of diabetic gastroparesis is poorly understood, in large
part due to the almost complete lack of data on neuropathological and molecular changes in the
stomachs of patients. Experimental models indicate various lesions affecting the vagus, muscle,
enteric neurons, interstitial cells of Cajal (ICC) or other cellular components. The aim of this study
was to use modern analytical methods to determine morphological and molecular changes in the
gastric wall in patients with diabetic gastroparesis.
Methods: Full thickness gastric biopsies were obtained laparoscopically from two gastroparetic
patients undergoing surgical intervention and from disease-free areas of control subjects
undergoing other forms of gastric surgery. Samples were processed for histological and
immunohistochemical examination.
Results: Although both patients had severe refractory symptoms with malnutrition, requiring the
placement of a gastric stimulator, one of them had no significant abnormalities as compared with
controls. This patient had an abrupt onset of symptoms with a relatively short duration of diabetes
that was well controlled. By contrast, the other patient had long standing brittle and poorly
controlled diabetes with numerous episodes of diabetic ketoacidosis and frequent hypoglycemic
episodes. Histological examination in this patient revealed increased fibrosis in the muscle layers as
well as significantly fewer nerve fibers and myenteric neurons as assessed by PGP9.5 staining.
Further, significant reduction was seen in staining for neuronal nitric oxide synthase, heme
oxygenase-2, tyrosine hydroxylase as well as for c-KIT.
Conclusion: We conclude that poor metabolic control is associated with significant pathological
changes in the gastric wall that affect all major components including muscle, neurons and ICC.
Severe symptoms can occur in the absence of these changes, however and may reflect vagal, central
or hormonal influences. Gastroparesis is therefore likely to be a heterogeneous disorder. Careful
molecular and pathological analysis may allow more precise phenotypic differentiation and shed
insight into the underlying mechanisms as well as identify novel therapeutic targets.
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Background
Long-standing and poorly-controlled diabetes may result
in many disturbances in gastrointestinal function of
which gastroparesis is one of the more common. In terti-
ary referral centers gastroparesis is seen in 20–55% of
patients with Type I and up to 30% of patients with type
II diabetes [1]. The pathogenesis of gastroparesis is poorly
understood, in part because of a lack of prospective com-
prehensive studies of gastric pathology in these patients.
Further, while animal models suggest that the pathogene-
sis of diabetic gastroparesis is likely to be multifactorial
involving the vagus, intrinsic nerves, interstitial cells and
smooth muscle of the stomach, the relative importance of
these elements in explaining variations in the clinical
presentation and natural history of patients remains
unknown [2]. Here we report the first systematic analysis
of gastric pathology in two humans with diabetic gas-
troparesis, using histological and immunohistochemical
techniques. Our results emphasize the heterogeneity of
this syndrome and provide several hypotheses for future
studies.
Methods
Patients
Both patients reported here were referred to the University
of Texas Medical Branch (UTMB) with a diagnosis of dia-
betic gastroparesis and refractory symptoms. The patients
consented to participate in a prospective study of full
thickness gastric biopsies obtained laparoscopically at the
time of surgical placement of a jejunal tube or gastric elec-
trical stimulator placement. All ages reported here are at
the time of the gastric biopsy.
Full thickness gastric biopsy
Full thickness pieces of tissue (1 × 2 cm in size) were taken
by the surgeon (GG) above the level of the incisura in the
anterior wall of the mid-body of the stomach. Control
specimens (n = 2) were obtained from the corresponding
area in non-diabetic obese patients undergoing gastric
bypass surgery by the same surgeon.
Pathological and immunohistochemical examination of 
tissue
For immunohistochemistry studies, biopsy specimens
were fixed in 4% paraformaldehyde (Sigma-Aldrich, St.
Louis, MO) in 1× phosphate buffer solution, rinsed in 1×
phosphate buffered saline (PBS) and immersed overnight
in 1× PBS solution containing 30% sucrose (Sigma-
Aldrich, St. Louis, MO). All incubations were completed
at 4°C. The biopsies were cut in cross section and frozen
in Tissue-Tek OCT compound (Electron Microscopy Sci-
ences, Hatfield, PA). 12 μm thick cryostat sections were
cut. A standard H&E and Trichrome stain protocol was
completed on the sections. The presence of fibrosis was
assessed using Masson's trichrome stain. For immunohis-
tochemistry six different antibodies were used following
the same protocol outlined below. The antibodies used
were a polyclonal rabbit anti-human protein gene product
9.5 (PGP 9.5) (1:2000, AbD Serotec, Oxford, UK), poly-
clonal rabbit anti-human neuronal nitric oxide synthase
(nNOS) (1:4000, Chemicon, Temecula, CA), polyclonal
sheep anti-rat tyrosine hydroxylase (TH) (1:200), polyclo-
nal rabbit anti-substance P (1:1200, Chemicon, Temec-
ula, CA), rabbit anti-human heme oxygenase II (HO-2)
(1:10,000, kind gift from Dr. Snyder, Johns Hopkins Uni-
versity, Baltimore, MA), polyclonal rabbit anti-human c-
Kit (2 ng/μl, MBL, Nagoya, Japan). The slides were first
rinsed twice in 1× PBS followed by a blocking step for
non-specific secondary antibody binding by incubating
the tissue with a 1× PBS, 10% normal donkey serum
(NDS; Jackson ImmunoResearch Lab, Inc., West Grove,
PA) and 0.3% Triton ×-100 (Pierce, Rockford, IL) solution
for one hour. The appropriate primary antibody was then
diluted in 1× PBS, 5% NDS, 0.3% Triton ×-100 and incu-
bated overnight at 4°C. A Cy3 conjugated donkey anti-
rabbit secondary antibody or a Cy3 conjugated donkey
anti-sheep secondary antibody (Jackson ImmunoRe-
search Lab, Inc., West Grove, PA) diluted in 1× PBS, 2.5%
NDS, 0.3% Triton ×-100 solution was used to visualize
the immuno-positive structures.
Institutional approval
This study was approved by the Institutional Review
Board of the University of Texas Medical Branch and the
Mayo Clinic College of Medicine. Informed consent was
obtained from all patients and controls.
Results
Clinical presentations
Case 1
This was a 37 year old white female who developed type
1 diabetes about 3 years prior to the biopsy. Gastroparetic
symptoms of nausea and vomiting were present for
approximately the same duration. Despite various thera-
pies, she continued to have severe nausea and vomiting,
along with weight loss. However, her diabetes remained
well controlled throughout with a HbA1c of 6.2% at ini-
tial presentation.
Case 2
This was a 32 year old white female with a history of type
I diabetes for about a decade. The diabetes was relatively
difficult to control with numerous episodes of diabetic
ketoacidosis and frequent hypoglycemic episodes. At the
time of presentation her HbA1c ranged between 6.6 to
7%. For more than a year prior to placement of a gastric
electrical stimulator, the patient had intractable symp-
toms of nausea, vomiting and pain with frequent hospi-
talizations.BMC Gastroenterology 2008, 8:21 http://www.biomedcentral.com/1471-230X/8/21
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Both patients had radiological and/or scintigraphic evi-
dence of severely delayed gastric emptying. Although for-
mal testing of the autonomic nervous system was not
carried out, both patients also had resting tachycardia
when they were relatively well, in the absence of overt
dehydration. Finally, the long-term (> 1 year) response to
gastric electrical stimulation was markedly different with
patient 1 reporting a more than 50% improvement in
symptoms as compared with baseline while patient 2
experienced no significant change in her clinical course.
Pathological changes in the stomach
Assessment of fibrosis (Figure 1)
Case 1
Sections from the patient with well controlled diabetes
showed a normal staining pattern with no evidence of
increased fibrosis in the muscle layers.
Case 2
In contrast, sections from the tissue obtained from the
patient with poorly controlled diabetes showed a marked
increase in fibrosis in both muscle layers and around the
myenteric plexus.
Enteric nerves (Figure 1)
The number of nerve cell bodies and fibers was assessed
using antibodies against the pan-neuronal maker PGP
9.5.
Case 1
The number of nerve fibers in the circular and longitudi-
nal muscle layers was normal in sections from the patient
with well controlled diabetes when compared to the con-
trols.
Case 2
There was a 40–50% decrease in the number of nerve fib-
ers in the patient with poorly controlled diabetes as com-
pared with controls.
Changes in the expression of neurotransmitters and related proteins 
(Figure 2)
Experiments were subsequently directed to determine if
the loss of nerve fibers seen was specific to a particular
subset of nerve fibers. Antibodies against tyrosine hydrox-
ylase (TH) were used to immunolabel extrinsic nerve fib-
ers. Antibodies against substance P (SP) and neuronal
nitric oxide synthase (nNOS) were used to immunolabel
excitatory nerves and inhibitory nerves respectively. Anti-
bodies to heme oxygenase-2 (HO2) were used to label
nerves and ICC that contain heme oxygenase, the enzyme
that gives rise to carbon monoxide, known to regulate
neurotransmission and smooth muscle membrane poten-
tial [3,4].
Case 1
No changes in expression of SP, nNOS, H02 (Figure 2)
were noted in sections from the patient with well control-
led diabetes when compared to controls. There was a
slight decrease in the number of TH positive fibers in the
muscle layers in this patient; however, TH immunoreac-
tivity around ganglia was normal, suggesting an intact
extrinsic innervation to the intrinsic nervous system (Fig-
ure 1).
Case 2
No significant changes were seen with the SP antibody but
immunolabeling for nNOS, H02 (Figure 2) and TH (Fig-
ure 1) was decreased (by 40–50%) in the patient with
poorly controlled diabetes.
Interstitial cells of Cajal
Human gastric ICC are of two major types- those that are
scattered throughout the stomach in both layers of muscle
(ICC-IM) and those that are associated with the myenteric
plexus (ICC-MY) in the body and antrum, but not in the
more proximal stomach. In this study, ICC were immu-
nolabeled using an antibody to c-Kit. ICC-MY were not
visualized in either patient nor in control tissue in this
region of the stomach.
Case 1
Distribution of ICC-IM was normal in the patient with
well controlled diabetes with normal numbers of ICC
(Figure 3).
Case 2
In the patient with poorly controlled diabetes the number
of c-Kit positive ICC-IM was reduced in both muscle layers
(by 30–40%, Figure 3).
Discussion
Despite its existence as a clinical syndrome for more than
half-a-century [5], the pathogenesis of diabetic gas-
troparesis remains unknown. Studies on experimental
models of diabetes have been relatively narrowly focused
on the interests of individual laboratories and indicate the
involvement of several cell types (neurons, ICC, muscle),
as reviewed recently [2]. The two most consistent findings
appear to involve changes in neuronal nNOS expression
and ICC. However, a unifying theme or hypothesis for
these findings has still not emerged in part because of the
inability to validate them in humans, in whom access to
the deeper intramural structures generally requires sur-
gery. The few studies that have obtained gastric tissue in
this manner were generally done in an era when sophisti-
cated imaging and molecular technologies did not exist
and have produced results that are inconsistent at best. We
report a systematic analysis of the gastric enteric nervous
system and muscle of two patients with diabetic gas-BMC Gastroenterology 2008, 8:21 http://www.biomedcentral.com/1471-230X/8/21
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Staining for fibrosis and for neuronal structures Figure 1
Staining for fibrosis and for neuronal structures. Panels A-C. Trichrome staining. The control (A) and sections from case 
1 (B) showed no increase in fibrosis, whereas sections from case 2 (C) showed an increase in fibrosis in both muscle layers and 
along the myenteric plexus. Scale bar 200 μm. Panels D-F. PGP 9.5 immunoreactivity. PGP9.5 immunoreactivity as a marker for 
neuronal structures was normal in control (D) and in case 1 (E). There was a decrease in PGP 9.5 immunoreactivity in both the 
muscle layers and the myenteric plexus in sections from case 2 (F) suggesting a loss of neuronal structures. Panels G-I. Tyro-
sine hydroxylase immunoreactivity. Tyrosine hydroxylase immunoreactivity was normal in the control (G). Sections from case 
1 (H) showing normal tyrosine hydroxylase immunoreactivity around the myenteric plexus with a lsight decrease in tyrosine 
hydroxylase immunoreactivity in the muscle layers. Sections from case 2 (I) showed a marked loss of tyrosine hydroxylase 
immunoreactivity in all regions suggesting a loss of extrinsic nerve fibers. Scale bar 100 μm. Circular muscle (CM), myenteric 
plexus (MP), longitudinal muscle (LM).BMC Gastroenterology 2008, 8:21 http://www.biomedcentral.com/1471-230X/8/21
Page 5 of 8
(page number not for citation purposes)
troparesis as compared with corresponding tissues
obtained from obese controls. Striking changes were seen
in one patient; these included a significant degree of fibro-
sis involving the muscle layer, which probably reflects the
consequences of severe and perhaps repetitive tissue
injury from metabolic, vascular or other complications of
diabetes.
Immunoreactiivty for nNOS, SP and HO2 as markers for inhibitory and excitatory nerve cell bodies and fibers Figure 2
Immunoreactiivty for nNOS, SP and HO2 as markers for inhibitory and excitatory nerve cell bodies and fibers. 
Panels A-C. Normal immunoreactivity for nNOS in control (A) and case 1 (B). nNOS immunoreactivity was markedly 
decreased in case 2 (C). Panels D-F. Substance P expression was normal in control (D), case 1 (E), and case 2 (F). Panels G-I. 
Heme Oxygenase II (HO-2) immunoreactivity was normal in control (G) and case 1 (H). Sections from Case 2 (I) showed a 
loss of HO-2 immunoreactivity which together with the decrease in nNOS immunoreactivty suggests a loss of inhibitory input 
ot smooth muscle. Scale bar 100 μm. Circular muscle (CM), longitudinal muscle (LM).BMC Gastroenterology 2008, 8:21 http://www.biomedcentral.com/1471-230X/8/21
Page 6 of 8
(page number not for citation purposes)
These changes are in keeping with a previous report show-
ing severe collagen deposition and fibrosis in 4 patients
with refractory diabetic gastroparesis [6,7]. On the other
hand, another study of 16 patients with long-standing
diabetes (five of whom had gastroparesis) showed no
abnormalities in the smooth muscle (or other structures)
[8]. Further, neither of these studies found any significant
changes in the myenteric plexus, which is in contrast to
our findings in Case 2, where a major reduction in mye-
nteric neuronal staining was seen along with a reduction
in markers for inhibitory neurotransmitters. Although we
did not study markers of apoptosis or cell death in this
study, the finding of decreased PGP9.5 labeling suggests
that these changes reflect a degree of neuronal loss and
not simply merely loss of expression of the synthetic
enzyme or neurotransmitter. However, evidence for actual
gastric neuronal loss in diabetes has not been reported in
either animals or patients [2], although a single case study
of a patient with idiopathic gastroparesis revealed mark-
edly reduced numbers of PGP 9.5-positive myenteric neu-
rons [9].
Nitric oxide is one of the most important neurotransmit-
ters for the maintenance of normal gastric motility and
there is considerable experimental literature implicating a
role for its loss in the pathogenesis of delayed gastric emp-
tying [10-19]. Most recently, a study of 36 male diabetic
patients undergoing gastric resection showed significant
loss of nNOS as well as SP expression; however, there was
no information on whether these patients were sympto-
matic or had impaired gastric motility [20]. In our patient
with poorly controlled diabetes, the reduction in overall
neuronal staining was accompanied by a significant loss
of nNOS, but not SP expression, suggesting relatively spe-
cific injury to inhibitory neurons. In this context, our
study is also the first to report changes in HO-2, the con-
stitutive form of heme oxygenase that is largely responsi-
ble for production of carbon monoxide, another
endogenous gaseous neuromodulator of considerable
importance in the inhibitory control of gastrointestinal
motility [3,21-25]. The combined loss of both inhibitory
molecules thus is expected to cause a profound distur-
bance of gastric physiology as was seen in our patient
(Case 2). This case also illustrates the differences and sim-
ilarities between changes in diabetic gastropathy as com-
pared with diabetic enteropathy. The latter is also
associated with loss of nNOS and TH expression but by
contrast, presents with increased expression of SP [26],
suggesting regional variations in the effects of diabetes on
the enteric nervous system.
Finally, we also looked at changes in ICC using c-Kit as a
marker. ICC play several critical roles in gastrointestinal
physiology including setting the pacemaker rhythm, and
participation in neurotransmission and mechanosensitiv-
ity [21,27-29]. Both in vivo and in vitro studies of experi-
mental diabetes report ICC depletion, perhaps secondary
to loss of insulin/IGF and/or nitric oxide or other, as yet
undetermined, survival factors [7,30-32]. Our findings of
significant loss of c-Kit expression in Case 2 are consistent
with other changes noted in this patient as well as with
emerging reports in humans. Thus, four out of nine
patients with refractory diabetic gastroparesis were found
to have significant loss of ICC [33]. A reduction in c-Kit
staining was also noted in the study on diabetic patients
undergoing gastric resection for cancer [20].
c-Kit expression as a marker for interstitial cells of Cajal Figure 3
c-Kit expression as a marker for interstitial cells of Cajal. Control (A) and case 1 (B) showed normal c-Kit immunore-
activity while in case 2 (C) there was a loss of c-Kit immunoreactivity suggesting a decreased number of ICC. Scale bar 100 μm. 
Circular muscle (CM), longitudinal muscle (LM).BMC Gastroenterology 2008, 8:21 http://www.biomedcentral.com/1471-230X/8/21
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Our study is important as it provides a rare insight into the
pathological as well as molecular changes of potential
importance in the pathogenesis of diabetic gastroparesis.
In addition, there are several noteworthy lessons from
these cases. To begin with, there appeared to be a clear cor-
relation between the histological changes noted and the
clinical course of diabetes, perhaps indicating the impor-
tance of poor glycemic control in their development. The
prevalence of delayed gastric emptying correlates weakly
with the duration of diabetes [34]. Related factors, such as
extreme hyper- or hypoglycemia, even if short-lived, may
be even more important as both conditions have been
shown experimentally to cause neuronal injury and death
(although hyperglycemia has not been shown to affect
ICC in an animal model) [31,35,36]. It is therefore possi-
ble that patient 1 was spared major changes in gastric
pathology because she experienced a shorter and metabol-
ically more stable course of diabetes than patient 2. The
only finding of note in the tissue from this patient was a
slight decrease in TH immunoreactivity in the circular
muscle layer but not in the myenteric plexus. Since the
extrinsic nervous system does not directly innervate
smooth muscle, these fibers could represent nerves tra-
versing their way to the submucosal plexus. Alternatively,
these could also be processes from intrinsic neurons as
there is a subset of enteric nerves that also expresses TH
[37]. Regardless, the clinicopathological implication of
this finding remains unclear.
More remarkable than the above observation, however,
was the fact that the changes in the stomach wall appeared
to have no relationship to clinical symptomatology. Thus,
despite comparable clinical severity, the two patients had
dramatically differences in gastric pathology, with one
being essentially normal and the other displaying a spec-
trum of abnormalities affecting nerve, muscle and ICC.
These findings provide room for several different specula-
tions. First, it is possible that the changes in Case 2 repre-
sent "end-stage" pathology resulting from cumulative and
repetitive metabolic insults. As such, their major clinical
significance may be to predict intractability rather than
causation, which is certainly suggested by the failure of
this patient to respond to all interventions including gas-
tric electrical stimulation. If this is true, then gastroparesis
symptoms themselves may be due to changes that either
occur earlier (such as perhaps the slight loss of TH immu-
noreactive fibers in the circular muscle layer) or are too
subtle to be detected by the techniques we have used (e.g.
abnormalities in subcellular signaling pathways in the
absence of morphological changes, as has been described
in gastric muscle from diabetic animals [38].
Secondly, it could be argued that our patients' symptoms
involved mechanisms that we did not investigate, such as
vagal dysfunction (suggested by the presence of resting
tachycardia in both cases). Changes in vagal function have
traditionally been implicated in the pathogenesis of gas-
troparesis, although solid evidence is lacking and the cor-
relation between autonomic dysfunction and delayed
gastric emptying is modest at best [2,34]. Finally, it is pos-
sible that diabetic gastroparesis is truly a heterogeneous
disorder and that while some patients have obvious gas-
tric pathology (as in case 2), others may develop a patho-
physiologically distinct form of gastroparesis resulting
from circulating autoimmune factors that can cause dys-
function but not disruption of the nerves or muscle, as has
been described [39,40].
Conclusion
In conclusion, we have described a detailed pathological
examination of two patients with diabetic gastroparesis.
While it is difficult to generalize based on such a small
number, these cases do offer some insight into the patho-
genesis of gastroparesis and also provide the basis for sev-
eral important hypothesis for future studies.
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